Clinical trials: Hepatic Tumors
Liver Cancer, Pain Postoperative
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
This phase III, randomized, prospective clinical study, aiming to compare the analgesic effects of celecoxib, parecoxib, and oxycodone in patients with inoperable hepatic carcinoma undergoing TACE procedure in postoperative pain…
- Trial name
- NCT03059238
- Testing
- Celecoxib 200mg oral capsule, parecoxib sodium, controlled-release oxycodone
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode
The purpose of this study is to prospectively compare the clinical outcomes (local tumor progression rate, technical success rate, complication rate) of no touch radiofrequency ablation (RFA) technique for Hepatocellular…
- Trial name
- NCT02806076
- Testing
- No-touch RFA arm, Conventional tumor puncture RFA arm
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Liver Cancer
Interventional X-ray and Scintigraphy Imaging of 99mTc-MAA During the Radioembolisation Pretreatment Procedure
To establish the safety and feasibility of interventional x-ray and scintigraphy imaging during the pre-treatment procedure of hepatic radioembolization
- Trial name
- IXSI (NCT06013774)
- Testing
- IXSI
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Hepatocellular Carcinoma
GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.
- Trial name
- NCT05047510
- Testing
- Anti-GPC3-IRDye800CW
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Liver Cancer
a Cohort Study (Gut Microbiota and HCC)
To analyze the predictive role of intestinal microbiota in tyrosine kinase inhibitors (TKIs) combined with immunotherapy response in patients with intermediate and advanced liver cancer.
- Trial name
- NCT06557213
- Volunteers
- 100 people
- Sponsor
- Xu Yong, MD
Hepatocellular Carcinoma
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
This study is an individualized anti-cancer vaccine protocol where the vaccination occurs inside of the body. To create the vaccine, a tumor lesion is selected and caused to die by a process called "Radiofrequency Ablation" or…
- Trial name
- NCT01923233
- Testing
- AlloStim
- Where
- Israel
- Sponsor
- Mirror Biologics, Inc.
Liver Cancer, Transplant; Failure, Liver
The Intention-to-treat Effect of Bridge Therapies in the Setting of Milan-in Patients
In patients with hepatocellular cancer (HCC) meeting the Milan Criteria (MC), the usefulness of loco-regional therapies (LRT) in the context of liver transplantation (LT) is still debated.
- Trial name
- NCT03723304
- Testing
- Bridging followed by transplant, Direct liver transplant
- Where
- Belgium
- Volunteers
- 1,083 people
- Sponsor
- European Hepatocellular Cancer Liver Transplant Group
Hepatocellular Carcinoma Non-resectable, Effect of Drug
Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)
As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) has become a big challenge all over the world. Most patients are not available to curative resection when first diagnosed.
- Trial name
- NCT05543304
- Testing
- radiological evaluation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Recurrent Hepatocellular Carcinoma
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
- Trial name
- TALENT (NCT04615143)
- Testing
- Tislelizumab, Tislelizumab combined with Levatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Hepatocellular Carcinoma
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT05312216
- Testing
- Durvalumab plus Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang University
Advanced Solid Tumors
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
- Trial name
- NCT07106814
- Testing
- Metabolically Armed TIL cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Anhui Provincial Hospital
Chronic Hepatitis B Virus (HBV) Infection
New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In France, it affects around 0.3% of the population.
- Trial name
- HBV-Biomark (NCT06906016)
- Testing
- Collection of blood samples for the study of HBV biomarkers
- Where
- France
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
The study is designed to determine whether loading doxorubicin (a type of chemotherapy), when loaded onto a drug eluting microsphere will result in increased destruction of a tumor.
- Trial name
- NCT01116635
- Testing
- doxorubicin, superabsorbent polymer microspheres, embolotherapy
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Carcinoma, Hepatocellular
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
- Trial name
- NCT00225290
- Testing
- Thalidomide(Thado)
- Where
- Taiwan
- Volunteers
- 230 people
- Sponsor
- TTY Biopharm
Liver Cirrhosis and Hepatoma., Gastric Variceal Bleeding
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic treatment.
- Trial name
- GVO-nadolol (NCT00567216)
- Testing
- Nadolol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
This study is a prospective, randomized controlled, multicenter clinical study. The purpose of this study is to explore the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with second-line regorafenib…
- Trial name
- NCT05233358
- Testing
- Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib
- Volunteers
- 176 people
- Sponsor
- The Central Hospital of Lishui City
Hepatocellular Carcinoma, Regorafenib
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
This is a single arm, nonrandomized, single center clinical study to investigate the safety and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma
- Conditions
- Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor
- Trial name
- NCT05048017
- Testing
- Regorafenib, PD-1 inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.